Effective visualization of integrated knowledge and data to enable informed decisions in drug development and translational medicine

Journal of Translational Medicine

Niclas Sjögren¹  Anders Bresell¹  Lena Brynne¹ 

[1] AstraZeneca, Södertälje SE-151 85, Sweden

关键词: Knowledge management;    Drug development;    Translational medicine;    Decision-making;    Visualization;    Informatics;    Clinical data;    Preclinical data;    Data integration;   

Others  :  825337
DOI  :  10.1186/1479-5876-11-250

 received in 2012-12-18, accepted in 2013-09-18,  发布年份 2013

【 摘 要 】

Integrative understanding of preclinical and clinical data is imperative to enable informed decisions and reduce the attrition rate during drug development. The volume and variety of data generated during drug development have increased tremendously. A new information model and visualization tool was developed to effectively utilize all available data and current knowledge. The Knowledge Plot integrates preclinical, clinical, efficacy and safety data by adding two concepts: knowledge from the different disciplines and protein binding.

Internal and public available data were gathered and processed to allow flexible and interactive visualizations. The exposure was expressed as the unbound concentration of the compound and the treatment effect was normalized and scaled by including expert opinion on what a biologically meaningful treatment effect would be.

The Knowledge Plot has been applied both retrospectively and prospectively in project teams in a number of different therapeutic areas, resulting in closer collaboration between multiple disciplines discussing both preclinical and clinical data. The Plot allows head to head comparisons of compounds and was used to support Candidate Drug selections and differentiation from comparators and competitors, back translation of clinical data, understanding the predictability of preclinical models and assays, reviewing drift in primary endpoints over the years, and evaluate or benchmark compounds in due diligence comparing multiple attributes.

The Knowledge Plot concept allows flexible integration and visualization of relevant data for interpretation in order to enable scientific and informed decision-making in various stages of drug development. The concept can be used for communication, decision-making, knowledge management, and as a forward and back translational tool, that will result in an improved understanding of the competitive edge for a particular project or disease area portfolio. In addition, it also builds up a knowledge and translational continuum, which in turn will reduce the attrition rate and costs of clinical development by identifying poor candidates early.

【 授权许可】

   
2013 Brynne et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

【 参考文献 】

• [1]Drolet BC, Lorenzi NM: Translational research: understanding the continuum from bench to bedside. Transl Res 2010, 157:1-5.
• [2]Gabrielsson J, Dolgos H, Gillberg P-G, Bredberg U, Benthem B, Duker G: Early integration of pharmacokinetic and dynamic reasoning is essential if lead compounds are to be developed optimally: strategic considerations. Drug DiscovToday 2009, 14:358-372.
• [3]Morgan P, Van Der Graaf PH, Arrowsmith J, Feltner DE, Drummond KS, Wegner CD, Street SDA: Can the flow of medicines be improved? fundamental pharmacokinetic and pharmacological principles toward improving phase II survival. Drug DiscovToday 2009, 17:419-424.
• [4]Visser SAG, Aurell M, Jones RDO, Schuck V, Egnell A-C, Peters S, Brynne L, Yates JWT, Jansson-Löfmark R, Tan B, Cooke M, Barry ST, Hughes A, Bredberg U: Model based drug discovery – implementation and impact. Drug Discov Today 2013, 18:764-775.
• [5]D360. http://www.certara.com/products/d360 webcite
• [6]Szalma S, Koka V, Khasanova T, Peraksils ED: Effective knowledge management in translational medicine. J Trans Med 2010, 8:68. BioMed Central Full Text
• [7]Napier C, Wallis R: The napiergram: a tool for visualising efficacy and safety data. J Pharm and Toxicological Methods 2010, 62(2):e12.
• [8]Korsan B, Dykstra K, Pullman W: Transparent trade-offs:a clinical utility index (CUI) openly evaluates a product’s attributes - and chance of success. Pharmceutical Executive 2005.
• [9]Poland B, Hodge FL, Khan A, Clemen RT, Wagner JA, Dykstra K, Krishna R: The clinical utility index as a practical multiattribute approach to drug development decisions. Clin Pharmacol Ther 2009, 86:105-108.
• [10]Ouellet D: Benefit-risk assessment: the use of clinical utility index. Expert Opin Drug Saf 2010, 9:289-300.
• [11]MeDRA. http://www.who.int/medical_devices/innovation/MedDRAintroguide_version14_0_March2011.pdf webcite
• [12]Seltzer B, Zolnouni P, Nunez M, Goldman R, Kumar D, Ieni J, Richardson S: Efficacy of donepezil in early-stage alzheimer disease. Arch Neurol 2004, 61:1852-1856.
• [13]Adam J, Ades AE, Aslan T, Barnett D, Brain E, Claxton K, Cookson R, Duncan F, Eccleston C, Ewings P, Feest T, Forbes A, Geddes J, Goulston J, Hands L, Haxby E, et al.: Alzheimer’s disease - donepezil, rivastigmine, galantamine and memantine (review) - final appraisal document: national institute for health and clinical excellence. NICE Guidelines 2006, 1-63. http://www.nice.org.uk/page.aspx?o=322952 webcite
• [14]Maher-Edwards G, Dixon R, Hunter J, Gold M, Hopton G, Hunter J, Williams P: Efficacy and tolerability of SB-742457, a novel 5HT6 receptor antagonist, and donepezil in subjects with mild-to moderate alzheimer’s disease (AD). Alzheimer’s & Dementia: J Alzheimer’s Association 2008, 4(4):T772-T773.
• [15]Birks J, Harvey RJ: Donepezil for dementia due to alzheimer’s disease. Cochrane Database Syst Rev 2006., 25CD001190
• [16]Gold M, Alderton A, Zvartau-Hind M, Ritchie S, Saunders A, Craft S, Landreth G, Linnamägi U, Sawchak S: Effects of rosigltazone as monotherapy in APOE4-stratified subjects with mild-to-moderate Alzheimer's disease. The Journal of the Alzheimer's Association 2009, 5(4):86.
• [17]Wehling M: Translational medicine: can it really facilitate the transition of research 'from bench to bedside’? Eur J Clin Pharmacol 2006, 62:91-95.
• [18]Wehling M: Assessing the translatability of drug projects: what needs to be scored to predict success? Nat Rev Drug Discov 2009, 8:541-546.
• [19]Wendler A, Wehling M: Translatability scoring in drug development: eight case studies. J Trans Med 2012, 10:39-49. BioMed Central Full Text
• [20]MeSH. http://www.ncbi.nlm.nih.gov/mesh webcite
• [21]Ruch P, Gobeill J, Lovis C, Geissbühler A: Automatic medical encoding with SNOMED categories. BMC Med Inform Decis Mak 2008, 8:S1-S6. BioMed Central Full Text
• [22]Sioutos N, de Coronado S, Haber MW, Hartel FW, Shaiu WL, Wright LW: NCI Thesaurus: a semantic model integrating cancer-related clinical and molecular information. J Biomed Inform 2007, 40:30-43.
• [23]Souza T, Kush R, Evans JP: Global clinical data interchange standards are here! Drug Discov Today 2007, 12:174-181.
• [24]Krishna R, Schaefer HG, Bjerrum OJ: Effective integration of system biology, biomarkers, biosimulation, and modeling in streamlining drug development. J Clin Pharmacol 2007, 47:738-43.